Vericel Corp

Vericel Corp’s Rule 144 filing signals a 15,000‑share sale and highlights its cutting‑edge stem‑cell technology poised to advance regenerative medicine.

Vericel Corp projects $276 M revenue in 2025, led by 23 % Q4 MACI growth, showing strong traction in regenerative medicine and a $1.95 B market cap.

Vericel Corp, a biotechnology company based in Cambridge, Massachusetts, is pioneering regenerative medicine through its proprietary Tissue Repair Cell technology, which harnesses the body’s own cells to heal and regenerate damaged tissues.

Vericel Corp’s latest financial results show a mixed bag, with a surprise beat on earnings per share but a revenue miss that raises concerns about the company’s market strategy and growth prospects.

Vericel Corp navigates financial challenges with a strategic pivot, raising profitability guidance and showcasing its innovative product pipeline, ahead of a key presentation at the Bank of America Securities 2025 Healthcare Conference.

Vericel Corp reports strong Q1 2025 financial results, exceeding market expectations and prompting a revision of its full-year profitability guidance.